ClinicalTrials.gg
RecruitingNCT06866938ReaLuPUpdated Jan 6, 2026

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

A Phase 2 interventional study of [177Lu]Lu-PSMA-617 (Pluvicto, Novartis) in Metastatic Castration-resistant Prostate Cancer, sponsored by Hospices Civils de Lyon. Recruiting at 16 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Hospices Civils de Lyon · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 9 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Planned enrollment
5th of 14
58 · median 31
Started
2025
the only one that year
Phase 2
3 of 14
1 open now
Registered
11th of 14
by date
Lead sponsor
1 of 14
Hospices Civils de Lyon

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Prostate cancer is the third leading cause of cancer-related death in men in the United States and Europe. The treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the arrival of the radioligand [177Lu]Lu-PSMA-617, which specifically targets PSMA-expressing cancer cells.

The randomized phase III VISION study showed that [177Lu]Lu-PSMA-617 significantly improved progression-free survival and overall survival with an acceptable toxicity profile.

The ReaLuP study will evaluate the efficacy of a re-treatment of [177Lu]Lu-PSMA-617 in patients with progressive PSMA-positive mCRPC and who have been previously treated with [177Lu]Lu-PSMA without evidence of progression during this first course of treatment.

Patients will be treated until disease progression, unacceptable toxicity or death, or alternatively up to 9 months after the last dose of treatment.

At the end of this follow up period, patients will enter the " long term follow up ", at least for 2 years after the end of the last active follow-up.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic castration resistance prostate cancer
  • Internal vectorized radiotherapy
  • [177Lu]Lu-PSMA rechallenge
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males ≥ 18 years of age
  • (ECOG) performance status ≤ 2 assessed within 7 days of study treatment initiation
  • or cytologically confirmed adenocarcinoma of prostate (Patients with small cell carcinoma of the prostate may be included)
  • disease documented by at least one lesion on bone scan or abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging (MRI) scan assessed by investigator. Patients without bone metastasis must have in extra-pelvic lymph nodes or in soft-tissues as defined by 1.1 criteria
  • Confirmed progression mCRPC despite ongoing androgen deprivation with serum testosterone \< 50ng/dl (1.7nM) within 3 months prior to screening. Progression is defined by the presence of at least one of the following criteria :

    • PSA progression using local laboratory values as defined by a minimum of 2 consecutive rising PSA levels with an interval of ≥1 week between each assessment where the PSA value at screening should be ≥1 ng/mL
    • Radiographic disease progression in bone based on PCWG3 criteria defined as the appearance of 2 or more new bone lesions on bone scan, with or without PSA progression
    • Radiographic disease progression in extra-pelvic lymph nodes based or soft-tissues on RECIST1.1 criteria with or without PSA progression
  • PSMA positive metastatic lesions on [68Ga]-PSMA-PET/CT without PSMA negative lesion (The presence of PSMA-positive lesions is defined as [68Ga]-PSMA-11 uptake greater than that of liver parenchyma in one or more metastatic lesions of any size in any organ system. The presence of PSMA-negative lesions is defined as PSMA uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any metastatic solid-organ lesions with a short axis of at least 1.0 cm, or in any metastatic bone lesion with a soft-tissue component of at least 1.0 cm in the short axis. Patients with any PSMA negative metastatic lesion meeting these criteria are ineligible).
  • Participants must have been previously treated with at least 4 consecutive cycles of [177Lu]Lu-PSMA with no evidence of progression during this first course of treatment (including radiological, clinical but also PSA progression).
  • Participants must have been previously treated with at least one ARSI - Androgen Receptor Signaling Inhibitors - (including enzalutamide, apalutamide, abiraterone or darolutamide) initiated for mCSPC, nmCRPC or mCRPC. (ARSI may be also administered together with [177Lu]Lu-PSMA-617 provided that the patient has not received an identical ARSI in the past and that this ARSI was initiated at least 15 days before the first cycle of [177Lu]Lu-PSMA-617 and less than 2 months ago. The ARSI administrated in association with LuPSMA should not be considered as a prior therapy. A previous ARSI treatment is mandatory for patient eligibility)
  • Patients must have been previously treated with at least one taxane based chemotherapy (with docetaxel or cabazitaxel) (The number of previously administrated lines of taxane-based therapy is not limited ; patients can have received a taxane-based chemotherapy before or after the first sequence of [177Lu]Lu-PSMA)
  • Patients must have been progressed at least 120 days after the last injection of the first course of [177Lu]Lu-PSMA therapy. (Patients with a radiological or clinical progressive disease during the first 120 days after the last cycle of the first course of [177Lu]Lu-PSMA are not eligible. PSA progression is defined by a ≥ 25% increase in PSA and an absolute increase of 2 ng/mL or more from the NADIR and confirmed by a second consecutive value obtained 3 or more weeks later. Patients treated with chemotherapy, ARSI or PARP inhibitors between the first 117LuPSMA course and screening are also eligible).
  • Be abstinent from heterosexual intercourse OR must agree to use unless confirmed to be azoospermic (vasectomized or secondary medical cause) until 98 days (14 weeks) post-treatment.
  • Adequate organ functions :

    • Bone marrow reserve :

      • ≥ 1.5 X 109/L
      • ≥ 100 X 109/L
      • ≥ 10 g/dL
    • Hepatic :

      • Total ≤ 2 x . For patients with known Gilbert's syndrome ≤ 3 x ULN.
      • (ALT) or aspartate aminotransferase (AST) ≤3 x ULN
    • Renal :

      • Clearance ≥40 ml/mn
  • Patients must have signed prior to participating in any study related procedures
  • Willing and able to comply with the protocol, including follow-up visits and examinations
  • Patients have to be affiliated to the French social security system, or equivalent

Exclusion criteria

Exclusion Criteria:

  • History of a [177Lu]Lu-PSMA serious adverse event (SAE) or Grade 3 or 4 AE during the initial course of [177Lu]Lu-PSMA that led to the discontinuation of treatment
  • More than one course of [177Lu]Lu-PSMA therapy
  • Less than 120 days from the last dose administrated in the initial course of [177Lu]Lu-PSMA treatment and the radiological or clinical disease progression, or the initiation of a subsequent therapy.
  • Any history of treatment with radium-223 dichloride or other systemic radiotherapy (including strontium-89, samarium-153, actinium-PSMA...)
  • Transfusion of red blood cells within 30 days prior to the first injection of the re-treatment of [177Lu]Lu-PSMA-617
  • Current central nervous system (CNS)
  • to the active substance (Lutetium [177Lu] vipivotide tetraxetan or Gallium [68Ga] gozetotide) or to any of the
  • Prior > hemibody external radiotherapy
  • Imminent or established spinal cord compression based on clinical findings and / or MRI that has not yet been treated
  • Other treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)
  • Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone)
  • Ongoing participation in any other clinical trial who may interfere with the present study in the judgment of the investigator
  • Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
  • Active cardiac disease
  • History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
  • Patients under tutorship or guardianship
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    [177Lu]Lu-PSMA-617

    Patients with metastatic castration resistance prostate cancer will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis) at the dose of 7.4 GBq (±10%) every 6 weeks Treatment duration: 4 to 6 cycles (24 to 36 weeks)

    Drug: [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)

Interventions

  • DrugLutetium-177Studies of Lutetium-177Lutetium-177 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis). One injection every 6 weeks at the dose of 7.4 GBq (±10%)

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival rate

    Proportion (in %) of patients alive without disease progression at 24 weeks. Progression is defined by imaging (bone scan and CT-scan) according to RECIST 1.1 and/or PCWG3 criteria.

    Time frame: At 24 weeks after the start of study treatment

Secondary outcomes

  1. Imaging-based radiographic progression (rPFS)

    Imaging-based radiographic progression defined as the time from the first cycle of re-treatment to the date of radiographic disease progression or death from any cause.

    Time frame: Through study completion, a maximum of 57 months

  2. Overall survival

    Overall Survival (Os) defined as the time from the first cycle of re-treatment to the date of death from any cause

    Time frame: Through study completion, a maximum of 57 months

  3. Objective response rate

    Objective response rate (ORR) (Complete Response (CR) + Partial Response (PR)) measured by RECIST v1.1 response.

    Time frame: Through study completion, a maximum of 57 months

  4. Duration of response

    Duration of response (DOR) will be measured in patients who achieved a CR or PR between the date of first response and the date of RECIST progression or death.

    Time frame: Through study completion, a maximum of 57 months

  5. Disease Control Rate

    Disease control rate as measured by RECIST v1.1 response. Rates will be measured in soft tissue, lymph nodes and visceral lesions.

    Time frame: Through study completion, a maximum of 57 months

  6. Progression free survival

    Progression free survival will be defined as the date of first cycle of \[177Lu\]Lu-PSMA-617 re-treatment to the date of first evidence of radiographic progression, clinical progression, PSA progression, or death from any cause, whichever occurs first.

    Time frame: Through study completion, a maximum of 57 months

  7. Biological response

    Proportion of participants with a PSA response defined as a patient who has achieved a ≥ 50% PSA decrease from baseline that is confirmed with a second PSA measurement at ≥ 4 weeks.

    Time frame: Through study completion, a maximum of 57 months

  8. Time to PSA progression

    Time to PSA progression will be defined as the date from first cycle of \[177Lu\]Lu-PSMA-617 re-treatment to a ≥ 25% increase in PSA and an absolute increase of 2 ng/mL or more from the nadir and confirmed by a second consecutive value obtained 3 or more weeks later. Where no decline from baseline is documented, PSA progression is defined as a 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 weeks of treatment.

    Time frame: Through study completion, a maximum of 57 months

  9. Safety : Adverse Events

    Safety of re-treatment will be assessed by percentage of patients with all grade and Serious AEs; percentage of patients with SAEs during the active follow up period; percentage of patients with an interruption of \[177Lu\]Lu-PSMA-617 re-treatment; Percentage of patients who discontinue \[177Lu\]Lu-PSMA-617 re-treatment secondary to an AEs or death; Number and grade of AE related to the investigational medicinal product or to the procedures added by the research

    Time frame: Through study completion, a maximum of 57 months

  10. Pain assessment

    Pain will be assessed with the BPI-SF (Brief Pain Inventory - Short Form) questionnaire. BPI-SF is a multidimensional scale evaluating the intensity and the interference of pain in life activities: four pain severity items and seven pain interference items rated on 0-10 scales, and the question about percentage of pain relief by analgesics. Pain severity: The BPI assesses pain at its "worst," "least," "average," and "now" (current pain); each of the forth items are used singly to represent pain severity. Pain interference: The BPI measures how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. BPI pain interference is typically scored as the mean of the seven interference items. This mean can be used if more than 50%, or four of seven, of the total items have been completed on a given administration. The highest is the score, the worst are the pain and pain interference

    Time frame: Up to 6 weeks from the last [177Lu]Lu-PSMA-617 administration

  11. Quality of life assessment

    Aspects of HRQoL will be reported using Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. FACT-P score range 0-156; the higher the score, the better the QoL Subscales: Physical well-being (0-28) Social/Family well-being (0-28) Emotional well-being (0-24) Functional well-being (0-28) Prostate cancer subscale (0-48)

    Time frame: Up to 6 weeks from the last [177Lu]Lu-PSMA-617 administration

  12. Symptomatic Skeletal Event (SSE) assessment

    Time to first symptomatic skeletal event (SSE) and SSE-free survival defined as date of first injection of \[177Lu\]Lu-PSMA-617 re-treatment to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, whichever occurs first.

    Time frame: Through study completion, a maximum of 57 months

07

Study locations

1 of 16 sites recruiting
  • Médecine Nucléaire, Institut Bergonié
    Bordeaux, 33000, France
    Not yet recruiting
  • Oncologie Médicale, CHU Brest-Hôpital Morvan
    Brest, 29200, France
    Not yet recruiting
  • Hôpital Louis Pradel, Hospices Civils de Lyon
    Bron, 69500, France
    Not yet recruiting
  • Oncologie Médicale, Centre François Baclesse
    Caen, 14076, France
    Not yet recruiting
  • Oncologie Médicale, Centre Jean Perrin
    Clermont-Ferrand, 63011, France
    Not yet recruiting
  • Médecine Nucléaire, Centre Hospitalier de Grenoble Alpes
    Grenoble, 38043, France
    Not yet recruiting
    • Loïc DJAÏLEB, MD/PhD · Contactldjaileb@chu-grenoble.fr · 04 76 76 54 55
    • Loïc DJAÏLEB, MD/PhD · Principal investigator
  • Médecine Nucléaire, Centre Léon Berard
    Lyon, 69373, France
    Not yet recruiting
  • Médecine Nucléaire, CHU de Nantes Hôtel-Dieu
    Nantes, 44000, France
    Not yet recruiting
  • Oncologie Médicale, Centre Antoine Lacassagne
    Nice, 06189, France
    Not yet recruiting
  • Institut de cancérologie du Gard
    Nîmes, 30000, France
    Not yet recruiting
  • Oncologie Médicale, Centre Hospitalier Lyon Sud, HCL
    Pierre-Bénite, 69310, France
    Recruiting
    • Denis MAILLET, Prof; MD/PhD · ContactDenis.maillet@chu-lyon.fr · 04 78 86 43 85
    • Denis MAILLET, Prof; MD/PhD · Principal investigator
  • Oncologie Médicale, Centre Henri Becqueret
    Rouen, 76038, France
    Not yet recruiting
  • Oncologie Médicale, CHU Saint Etienne
    Saint-Priest-en-Jarez, 42270, France
    Not yet recruiting
  • Médecine Nucléaire, Institut de Cancérologie de Strasbourg
    Strasbourg, 67200, France
    Not yet recruiting
    • François SOMME, MD · Contactf.somme@icans.eu · 03 68 76 67 67
    • François SOMME, MD · Principal investigator
  • CHU de Nancy
    Vandœuvre-lès-Nancy, 54511, France
    Not yet recruiting
    • Marine CLAUDIN, MD · Contactm.claudin@chru-nancy.fr · +333 83 15 71 72
    • Marine CLAUDIN, MD · Principal investigator
  • Médecine Nucléaire, Institut Gustave Roussy
    Villejuif, 94800, France
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 24 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 10, 2025
StartActual
Apr 11, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2030
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06866938
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Apr 11, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2030 (estimated)
Last update
Jan 6, 2026

Study contacts

Denis MAILLET, Prof; MD/PhD
Contact
Denis.maillet@chu-lyon.fr
04 78 86 43 85 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion